Worth Venture Partners, LLC Rigel Pharmaceuticals Inc Transaction History

Worth Venture Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $595,663 - $876,603	-177,810 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$2.35 - $3.74 $417,853 - $665,009	177,810 New	177,810 $622,000
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $380,991 - $883,985	-214,040 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$1.41 - $2.05 $168,282 - $244,665	-119,349 Reduced 35.8%	214,040 $391,000
Q1 2020 May 15, 2020	BUY	$1.27 - $3.0 $407,320 - $962,175	320,725 Added 2532.57%	333,389 $520,000
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $380,846 - $578,410	-238,029 Reduced 94.95%	12,664 $27,000
Q3 2019 Nov 12, 2019	BUY	$1.63 - $2.62 $37,082 - $59,605	22,750 Added 9.98%	250,693 $469,000
Q2 2019 Aug 14, 2019	BUY	$2.02 - $2.61 $17,776 - $22,968	8,800 Added 4.02%	227,943 $595,000
Q1 2019 May 15, 2019	BUY	$2.0 - $2.65 $263,486 - $349,118	131,743 Added 150.74%	219,143 $463,000
Q4 2018 Feb 15, 2019	BUY	$2.08 - $3.36 $160,992 - $260,064	77,400 Added 774.0%	87,400 $200,000
Q3 2018 Nov 15, 2018	BUY	$2.6 - $3.59 $26,000 - $35,900	10,000 New	10,000 $32,000

355K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.8B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.